Advanced Targeting Systems

Chronic pain is often difficult to pinpoint--witness the strange phenomenon of phantom limb pain, where patients continue to feel pain years after an amputation. Advanced Targeting Systems believes it can target a toxin known as saporin to the neurons that express substance P receptors, to permanently knock out chronic pain while leaving useful pain sensation intact.

"Pain is good," asserts Douglas Lappi, PhD, president and founder of Advanced Targeting Systems . "People who lack the ability to sense pain have very shortened life spans." The trick, says Lappi, is to short-circuit the signals that cause chronic, intractable pain and leave intact the body's ability to detect incoming pain stimuli like heat, chemicals, or injury. In the US, 70 million people suffer from chronic pain. Many disorders cause people to become hypersensitive to stimuli that otherwise would not cause pain. Many people also suffer from pain that persists in the absence of an ongoing injury, such as sufferers of phantom limb pain, reflex sympathetic dystrophy, and diabetic neuropathy. The company believes it has found a solution to these types of pain syndromes in the permanent elimination of neurons in the spinal cord which express receptors for substance P.

Substance P is a neurotransmitter that is implicated in several disorders, including cancer, asthma, emesis, depression, and pain. Capsaicin, a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

Regeneron Plans To File Cemdisiran For gMG But Will Face Tough Market

 

Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By 

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By 

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.